Assay Report
Methods · Standard Curves · QC · Results
Comprehensive single-molecule digital immunoassay services for quantifying ultra-low-abundance protein biomarkers in plasma, serum, CSF, tears, saliva, cell supernatants, and tissue lysates down to sub-picogram and femtogram per milliliter limits.
By resolving decision-critical biomarkers that fall below the detection thresholds of conventional plate ELISAs and standard multiplex platforms, our Simoa facility enables non-invasive blood-based biomarker quantification, longitudinal micro-sampling in small animal cohorts, and fit-for-purpose preclinical bioanalysis.
Validated commercial kits, multiplex panels, and custom single-molecule digital assay development portfolios.
| Assay Service & Biomarker Target | Core Target Analytes | Sensitivity (LLOQ) | Preclinical Research & Application Focus |
|---|---|---|---|
| Neurofilament Light (NfL) Testing | Neurofilament Light (NfL) | 0.05 – 0.10 pg/mL | Universal fluid biomarker of active axonal degradation in amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), and neurotoxicity pipelines. |
| Phosphorylated Tau-217 (p-Tau217) Assay | Phosphorylated Tau-217 | 0.01 – 0.02 pg/mL | Earliest blood-based surrogate of cortical amyloid-beta plaque accumulation utilizing ALZpath antibody configurations. |
| Multi-Epitope Tau Profiling | Total Tau, p-Tau181, p-Tau231, BD-Tau | 0.01 – 0.06 pg/mL | Dynamic phosphorylation cascades, tauopathy differential staging, and phospho-to-total Tau ratio analytics. |
| Brain-Derived Tau (BD-Tau) Assay | Brain-Derived Tau (BD-Tau) | 0.02 – 0.05 pg/mL | Specific measurement of CNS-derived tau fragments in blood, eliminating non-brain peripheral total Tau background. |
| Alpha-Synuclein (α-Syn) Assay | Total and Oligomeric α-Syn, pS129 | 0.02 – 0.10 pg/mL | Synucleinopathy staging in Parkinson's disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and neuron-derived extracellular vesicles (NDEVs). |
| Neurodegeneration Biomarker Panel Design | NfL, GFAP (glial fibrillary acidic protein), UCH-L1 (ubiquitin C-terminal hydrolase L1), Total Tau, Aβ42/40 | 0.05 – 1.80 pg/mL | Synchronized multi-cellular tracking: axonal loss (NfL), astrogliosis (glial fibrillary acidic protein [GFAP]), acute neuronal cytolysis (ubiquitin C-terminal hydrolase L1 [UCH-L1]), and amyloid. |
| Cytokine & Inflammation Profiling | IL-1β, IL-6, TNF-α, IL-10, IFN-γ, MCP-1 | 0.01 – 0.05 pg/mL | Sub-pg/mL basal cytokine tracking in unstimulated blood/tears, cytokine release syndrome (CRS), and immune monitoring. |
| Type 2 & Allergic Cytokine Panel | IL-4, IL-5, IL-13, IL-33, TSLP (thymic stromal lymphopoietin), IL-17A | 0.02 – 0.05 pg/mL | Eosinophilic asthma, atopic dermatitis, epithelial alarmin signaling, and mucosal barrier remodeling. |
| Custom Simoa Immunoassay Development | Proprietary targets, novel mAbs, neoantigens | Sub-pg/mL (Empirical) | De novo assay design, EDC/NHS bead coupling, detector biotinylation, and FDA Bioanalytical Method Validation (BMV) / International Council for Harmonisation (ICH) M10 bioanalytical validation. |
Evaluating analytical performance, multiplex capacity, sample volume consumption, and detection boundaries across bioanalytical platforms.
| Technical Dimension | Conventional Plate ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa HD-X |
|---|---|---|---|---|
| Analytical Sensitivity (LLOQ) | 10.0 – 50.0 pg/mL | 1.0 – 10.0 pg/mL | 0.5 – 5.0 pg/mL | 0.005 – 0.10 pg/mL (Sub-pg/mL / fg/mL) |
| Basal Blood Detectability | <25% (High non-detect rate) | 50% – 70% (Baseline dropout risk) | 70% – 85% (CSF optimal; plasma variable) | 100% Quantifiable across healthy cohorts |
| Sample Consumption per Test | 50 – 100 μL (Neat) | 25 – 50 μL (Shared) | 25 – 50 μL | 15 μL net volume (1:4 dilution) |
| Multiplex Capacity | Singleplex (1 analyte/well) | High Multiplex (Up to 50–100 plex) | Medium Multiplex (1–10 plex) | Focused Low-Plex (1–4 plex) |
| Linear Dynamic Range | 2.0 – 2.5 logs | 3.0 – 3.5 logs | 4.0 – 5.0 logs | >4.5 logs (Poisson digital + Analog) |
| Optical / Spectral Crosstalk | N/A (Individual wells) | Low (Bead deconvolution) | Low (Spatial spot separation) | Zero (Digitally isolated femtoliter wells) |
| Serial Rodent Survival Bleeds | Poor (Requires terminal pooling) | Moderate | Moderate | Excellent (Serial tail-vein / submandibular) |
| Primary Matrix Fit | In vitro cell models | Large multi-species discovery | CSF, tissue lysates, high-abundance | Peripheral blood (serum/plasma), micro-fluids |
Automated fluidic robotics, digital Poisson counting algorithms, and quality verification.
Digital Poisson counting at sub-pg/mL levels converts active well ratios into absolute Average Enzymes per Bead (AEB) with zero bulk-solution background noise.
Automated transition between single-molecule digital counting and bulk analog fluorescence intensity accommodates up to 4.5 logs of concentration without manual re-dilution.
Standardized 1:4 on-board dilution (15 μL neat volume) across biological matrices supplemented with active heterophilic blocking reagents to eliminate matrix interference.
Barcode verification on dry ice, visual assessment for hemolysis/lipemia, cataloged into monitored -80°C biobanking.
Liquid handler performs 1:4 dilution in matrix-matched diluent supplemented with heterophilic blocking agents.
Target analytes are captured onto antibody-coated paramagnetic beads, followed by biotinylated detector binding and enzyme labeling.
Bead-enzyme complexes are partitioned into 216,000 microwells on Simoa discs, oil-sealed, and imaged for digital enzyme counting (AEB).
Software algorithms interpolate AEB values against 4PL/5PL calibration curves to output absolute pg/mL concentrations, replicate CVs, and QC metrics.
Standardized pre-analytical controls ensuring biomarker stability and eliminating matrix-induced suppression.
| Pre-Analytical Parameter | Why It Matters for Ultra-Sensitive Assays | Intake Specification & Recommendation |
|---|---|---|
| Anticoagulant Selection | Heparin tubes cause polyanionic charge competition and reduce apparent signals; K2-EDTA preserves antigen stability. | K2-EDTA plasma is strongly preferred; serum is acceptable if clotted for 30–60 min at RT and promptly centrifuged. |
| Centrifugation Timing | Delayed separation of whole blood at room temperature causes cellular lysis and release of intracellular proteins. | Centrifuge at 2,000 × g for 15 min at 4°C within 60 minutes of collection; harvest cell-free supernatant. |
| Freeze-Thaw Control | Protein biomarkers undergo conformational degradation and aggregation upon repeated temperature cycling. | Aliquot immediately into polypropylene cryovials; store at -80°C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | Single-molecule digital counting requires minimal specimen input, conserving small-animal biofluids. | 15 μL net volume per well (30–50 μL recommended for duplicate verification and reserve). |
| Matrix Parallelism | Complex matrices (CSF, ocular fluids, cell supernatants) require validation of minimum required dilution. | Provide unconditioned media controls or matrix blanks during study intake. |
Applying ultra-sensitive single-molecule digital immunoassays across neuroscience, immunology, oncology, and safety.
Track fluid biomarker cascades across preclinical Alzheimer's (p-Tau217, Multi-Epitope Tau, BD-Tau), Parkinson's (α-Syn), and ALS.
Quantify acute cytolytic markers (UCH-L1, GFAP) alongside chronic subacute axonal degradation (Simoa NfL Testing).
Measure basal pro-inflammatory (Simoa Cytokines) and Th2 allergic mediators (Simoa Th2 Panel) in blood without ex vivo stimulation.
Build bespoke digital single-molecule assays for proprietary targets, neoantigens, and novel mAbs (Custom Simoa Development).
Screen novel small molecules, antibody-drug conjugates (ADCs), and AAV gene therapies for structural and inflammatory liabilities.
Seamlessly bridge data between orthogonal bioanalytical platforms using our dedicated MSD Assay Service and Luminex Solutions.
Standardized bioanalytical documentation, statistical curve fitting, and senior scientist consultation.
Key peer-reviewed publications establishing single-molecule digital immunoassay physics, automated instrumentation, and clinical utility.
Study Design Takeaway: Establishes the foundational physics of digital Poisson single-molecule enzyme counting in femtoliter microwells, demonstrating up to 1000-fold sensitivity gains over conventional ELISA.
Study Design Takeaway: Details the automated instrument engineering, paramagnetic bead transport, and optical disc imaging that enable robust single-molecule immunoassay performance.
Study Design Takeaway: Validates the superior clinical diagnostic and prognostic performance of automated plasma Simoa biomarkers (p-Tau217, p-Tau181, NfL, GFAP) across longitudinal cohorts.
Study Design Takeaway: Demonstrates robust single-molecule quantification of basal cytokines in human plasma and establishes practical method-bridging parameters against legacy multiplex systems.
Addressing common project planning, matrix validation, and technology selection inquiries.
Simoa captures target protein molecules onto 2.7 μm paramagnetic beads and isolates individual beads into microfabricated arrays of 216,000 femtoliter-sized reaction wells on optical discs. By confining the enzymatic fluorescent product to a volume over 2 billion times smaller than standard ELISA wells, a single immunocomplex generates a rapidly detectable local signal. Digital Poisson statistics (Average Enzymes per Bead) are applied to quantify concentrations at the single-molecule level.
Simoa assays are validated across human, non-human primate, mouse, rat, canine, and porcine matrices. Compatible biofluids include K2-EDTA plasma, serum, cerebrospinal fluid (CSF), tears, ocular fluids, saliva, urine, cell culture supernatants, and brain tissue homogenates.
The standard protocol requires only 15 μL of neat sample volume per well (which is diluted 1:4 on-board to a 60 μL working volume). We recommend providing 30–50 μL total volume to support dead volume and duplicate confirmation.
Yes. Through our Custom Simoa Immunoassay Development service, we convert client-supplied matched antibody pairs or standard ELISAs into custom digital assays via EDC/NHS magnetic bead coupling and biotinylation optimization, achieving sub-picogram quantification limits.
Cross-platform comparisons should be treated as a formal method bridging exercise. While relative group rankings and fold-changes correlate strongly (r > 0.95), variations in calibrator constructs, antibody affinities, and dilution factors introduce minor numerical offsets. We provide paired bridging studies to establish mathematical conversion algorithms for long-term programs.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical drug discovery, animal disease models, translational research cohorts, and in vitro cellular characterization, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×